Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 21;23(6):71.
doi: 10.1007/s11912-021-01053-7.

Update on Osteosarcoma

Rebekah Belayneh  1 , Mitchell S Fourman  1 , Sumail Bhogal  1 , Kurt R Weiss  2
Affiliations
Review

Update on Osteosarcoma

Rebekah Belayneh et al. Curr Oncol Rep. .

Abstract

Purpose of review: Osteosarcoma (OSA) is the most common primary tumor of bone, mainly affecting children and adolescents. Here we discuss recent advances in surgical and systemic therapies, and highlight potentially new modalities in preclinical evaluation and prognostication.

Recent findings: The advent of neoadjuvant and adjuvant chemotherapy has markedly improved the disease-free recurrence and overall survival of OSA. However, treatment efficacy has been stagnant since the 1980s. This plateau has prompted preclinical and clinical research into in precision surgery, inhaled chemotherapy to increase pulmonary drug concentration without systemic side effects, and novel immunomodulators intended to block molecular pathways associated with OSA proliferation and metastasis. With the advent of novel surgical techniques and new forms and vectors for chemotherapy, it is hoped that OSA treatment outcomes will exceed their currently sustained plateau in the near future.

Keywords: Aerosolized chemotherapy; Aldehyde dehydrogenase; Chimeric antigen receptor T-cell therapy; Doxorubicin; GD2 inhibition; Gemcitabine; Indocyanine green; Limb salvage; Metastasis; Methotrexate; Near-infrared imaging; Osteosarcoma; Pazopanib; Pediatric sarcoma; Sorafenib.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance
    1. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am. 2000;82:667–74. - PubMed
    1. Cho WH, Song WS, Jeon D-G, Kong C-B, Kim MS, Lee JA, et al. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations. Ann Surg Oncol. 2010;17:702–8. - PubMed
    1. Abate ME, Longhi A, Galletti S, Ferrari S, Bacci G. Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger. Pediatr Blood Cancer. 2010;55:652–4. - PubMed
    1. Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21:2011–8. - PubMed
    1. Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JAM, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer. 2009;45:2367–75. - PubMed

LinkOut - more resources